Mandate

Vinge has advised Corline Biomedical AB (publ) in connection with a directed share issue

The share issue was directed to a number of Swedish and international institutional investors on the basis of an accelerated bookbuilding process.

Corline intends to use the issue proceeds to continue the development of Renaparin® in phase 2 clinical development to interim data, build the organisation to increase proceeds to the medical technology branch, improve the financial flexibility and strengthen the working capital.

Vinge’s team has consisted of Dain Hård Nevonen, Amanda Knutsson and Clara Sohlberg.

Related

Vinge has represented Inflexion in connection with the acquisition of Mecenat

Vinge has represented Inflexion in connection with the acquisition of the Mecenat group from IK. The acquisition of Mecenat is the first investment made through Inflexion's new Enterprise Fund VI, and Inflexion's first acquisition in Sweden.
January 14, 2025

Vinge has advised the sellers in connection with the sale of Färskvaruhuset i Göteborg AB

Färskvaruhuset i Göteborg AB is a Swedish nationwide supplier to the retail sector within meat and poultry as well as charcuterie and delicatessen products. The acquirer was the international food trading company BPI A/S, headquartered in Denmark.
January 13, 2025

Vinge has advised the seller in conjunction with the sale of Lundby Plåt Aktiebolag

Lundby Plåt Aktiebolag provides services within sheet metal work. The acquirer was the Gothenburg based contracting and construction services company, Göfast Gruppen AB.
January 13, 2025